Latest

3 stories

Hide weekly roundups

Monday, August 3

ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply deal

ORIC reported second quarter 2026 results with the Himalayas-1 prostate cancer trial underway, a darolutamide supply pact with Bayer, and cash guided into second half 2028.

SEC filing

Thursday, July 30

PeopleORIC Pharmaceuticals

ORIC Pharmaceuticals expands inducement equity plan by 1.1 million shares

The board approved an amended inducement plan on July 28, 2026, raising total reserved shares to 3,350,000 for awards to new hires.

SEC filing

Thursday, July 23

ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPC

Trial updateBayer darolutamide